JAK2 Gene, V617F Mutation, Quantitative
0040168
 
Ordering Recommendation
Quantitates JAK2 V617F allele frequency in enriched granulocytes from peripheral whole blood. Aids in risk stratification and therapeutic monitoring of JAK2 V617F mutation positive myeloproliferative neoplasms.
Mnemonic
JAK2 QNT
Methodology
Polymerase Chain Reaction
Performed
DNA isolation: Sun-Sat
Assay:
Mon, Wed, Fri
Reported
7-10 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA).  
Specimen Preparation
Transport 5 mL whole blood. (Min: 1 mL)..  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Bone marrow, serum, or plasma. Frozen or clotted whole blood. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens.  
Remarks
 
Stability
Ambient: 24 hours; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
By report
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Note
CPT Code(s)
81270
Components
Component Test Code*Component Chart Name
0040167JAK2 Gene, V617F Mutation, Quantitative
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • BCR-ABL1-negative tesing
  • Classic BCR-ABL1-negative MPN testing
  • MPN JAK 2
  • mutant JAK 2 V617F allelic burden